Ranopril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranopril

What is Ranopril?

Ranopril is a pharmaceutical medication belonging to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily utilized in the management of cardiovascular conditions, specifically for the treatment of high blood pressure (hypertension) and heart failure.

Mechanism of Action

The medication works by interfering with the body's production of angiotensin II, a potent chemical that causes blood vessels to tighten and narrow. By inhibiting the enzyme responsible for creating this chemical, Ranopril allows blood vessels to relax and widen. This process results in:

  • Reduced blood pressure: Lowering the pressure within the arteries.
  • Decreased cardiac workload: Making it easier for the heart to pump blood throughout the body.
  • Improved blood flow: Enhancing circulation to vital organs.

Therapeutic Use

In clinical practice, Ranopril is often prescribed to improve survival rates following a heart attack or to protect kidney function in patients with certain types of diabetes. It is frequently used as a long-term maintenance therapy to help prevent future cardiovascular events such as strokes and further heart complications.

As a systemic treatment, it is absorbed through the digestive tract and distributed via the bloodstream to maintain consistent levels of vessel relaxation over a 24-hour period.

Regulatory References

  1. Lisinopril: MedlinePlus Drug Information

What side effects are possible with Ranopril?

Possible Side Effects and Safety Information

The safety profile for Ranopril is based on official government regulatory documentation, detailing adverse effects by frequency and system-organ class.

Serious Safety Restrictions

Fetal Toxicity (Boxed Warning): Use during the second and third trimesters of pregnancy is associated with fetal injury and death. Treatment must be discontinued immediately upon detection of pregnancy.

Angioedema: A serious, potentially life-threatening allergic-type reaction involving swelling of the face, limbs, lips, tongue, or throat, which can cause airway obstruction. Immediate medical attention is required.

Common Adverse Reactions

Adverse reactions reported as Common in clinical studies include:

  • Cough (non-productive)
  • Headache
  • Dizziness and Fatigue
  • Diarrhoea and Vomiting
  • Increased blood potassium (hyperkalemia)
  • Postural hypotension (low blood pressure upon standing)

Clinically Significant and Systemic Adverse Effects

Adverse reactions are formally categorized by the affected body system, including effects on the Renal and urinary system (such as renal impairment and acute renal failure), Hepatobiliary system (including rare cases of fatal hepatic failure), and Blood and lymphatic system (such as agranulocytosis or neutropenia).

First-Dose Hypotension: A temporary, significant drop in blood pressure can occur after the initial dose, especially in patients who are severely volume- or salt-depleted.

Limitations: Ranopril is contraindicated in patients with a history of angioedema related to a previous ACE inhibitor treatment or in those with bilateral renal artery stenosis. Monitoring of blood pressure, kidney function (creatinine/BUN), and serum potassium levels is indicated during therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Lisinopril (Ranopril) is primarily characterized by an exaggerated pharmacological effect resulting in severe hypotension (excessive low blood pressure), which is the most frequent clinical manifestation documented in regulatory labeling. Officially listed signs associated with this event include tachycardia (increased heart rate), bradycardia (slowed heart rate), palpitations, and dizziness.

Regulatory documents state that an overdose can lead to severe and potentially life-threatening outcomes, such as circulatory shock and acute renal failure, along with major electrolyte disturbances. Due to the severity of these potential complications, emergency medical treatment must be sought immediately if an overdose is suspected.

Management of this condition is documented as being symptomatic and supportive, particularly because no specific antidote is known. Officially described procedural steps include using intravenous infusion of normal saline solution and placing the patient in the supine position to manage severe hypotension. In cases of significant exposure, Lisinopril may be removed from the general circulation using haemodialysis. This official profile strictly outlines the mandated response to the documented risks.

Therapeutic Uses of Ranopril

What Ranopril Treats: Main Uses and Benefits

Ranopril (Enalapril) is a medication generally used to help manage conditions related to systemic imbalance in the cardiovascular and renal systems. Ranopril is a treatment option for chronic hypertension (high blood pressure) and may be used in combination with other medications to help manage heart failure.

The primary therapeutic use is applied across domains where additional symptomatic support is needed for individuals managing blood pressure control, heart conditions, and certain types of kidney disease. It helps address symptom clusters that may become intense or disruptive, such as the fluid retention and breathing difficulties associated with heart failure.

“Ranopril provides supportive relief that helps patients cope more steadily with the underlying pathology, contributing to easing the overall symptom load.”

This medication is relevant in contexts involving heightened systemic burden, particularly for patients with diabetes or existing risk factors, where it plays a role in managing organ-specific functional stress. The overall benefit is that it supports the heart's function and may assist with maintaining functional stability, thereby contributing to improved day-to-day comfort.


Quick Fact: Relief for Swelling & Shortness of Breath Ranopril is commonly used to help manage fluid retention and breathing difficulties associated with heart failure, which are symptoms that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Ranopril (Ramipril) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose eligibility is strictly defined by regulatory contraindications and restrictions.

Populations Who Must Not Use Ranopril (Contraindicated)

  • Pregnancy: Use is strictly contraindicated during the second and third trimesters, and it must be discontinued immediately upon detection of pregnancy due to risk of fetal harm and death.
  • Prior Angioedema: The drug is contraindicated in patients with a history of angioedema (severe swelling) related to previous ACE inhibitor treatment, or in those with hereditary or idiopathic angioedema.
  • Hypersensitivity: Patients with known hypersensitivity to Ramipril, or any other ACE inhibitor, must not use this medicine.
  • Drug Combinations: Use is contraindicated within 36 hours of taking a neprilysin inhibitor (e.g., sacubitril). Co-administration with aliskiren is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m^2).

Eligibility-Related Restrictions

  • Lactation/Nursing: Use is not recommended in breastfeeding women due to unknown risks to the infant.
  • Pediatrics: Safety and efficacy are generally not established; use is not recommended in children under 6 years of age.
  • Organ Function: Use requires special caution in patients with bilateral renal artery stenosis, severe hepatic impairment, or significant volume depletion/hypotension. Dose adjustment is typically required in patients with impaired kidney function.

What should I know about interactions with other medicines?

Ranopril (Lisinopril) has documented interaction patterns that primarily involve pharmacodynamic and clearance effects as described in regulatory labeling.

Contraindicated Combinations

Co-administration with Neprilysin inhibitors (e.g., Sacubitril/Valsartan) is formally contraindicated due to a significantly increased risk of angioedema. A mandatory 36-hour washout period is required when switching between these agents. Furthermore, the combination with Aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment due to the risk of hypotension, hyperkalemia, and renal dysfunction.

Other Clinically Significant Interactions

Interactions affecting electrolyte balance are documented: combining Ranopril with potassium-sparing diuretics (e.g., Spironolactone) or potassium supplements officially increases the risk of hyperkalemia (high blood potassium).

The co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be associated with a documented risk of renal function deterioration and a potential reduction in antihypertensive efficacy. Co-administering Ranopril with Lithium is officially noted to alter renal clearance and raise serum Lithium levels, increasing the risk of toxicity.

Since Lisinopril is not metabolized by the CYP enzyme system, no CYP-mediated drug interactions are described. Reduced renal function and advanced age are noted in regulatory documents to decrease Lisinopril clearance, resulting in higher plasma concentrations. Ranopril absorption is not affected by food, but alcohol consumption may enhance the hypotensive effect.

Mechanism of Action

Ranopril is a prodrug that is bioactivated in the liver to its principal metabolite, Ranoprilat. Ranoprilat functions as a competitive inhibitor of the enzyme angiotensin-converting enzyme (ACE), also known as kininase II.

ACE is the biological target responsible for cleaving circulating Angiotensin I to form the potent vasoconstrictor peptide, Angiotensin II (Ang II), a key component of the renin-angiotensin-aldosterone system (RAAS). Inhibition of ACE by Ranoprilat blocks the synthesis of Ang II, leading to a downstream reduction in Ang II plasma concentrations and tissue levels.

Reduced Ang II concentration results in less activation of its cognate Angiotensin II Type 1 ( AT1) receptors, which are Gq-coupled protein receptors. This diminished signaling decreases Gq-mediated intracellular pathways that stimulate arterial vasoconstriction and Aldosterone release from the adrenal cortex. The molecular pathway also involves a reduction in Ang II-mediated degradation of the vasodilatory peptide Bradykinin, leading to increased Bradykinin levels.

The system-level physiological consequence is a reduction in total peripheral vascular resistance due to vasodilation, and a decrease in sodium and water reabsorption in the renal distal convoluted and collecting tubules due to lowered Aldosterone levels, modulating fluid volume and vascular tone.

Dosage and Administration Information

How to Use Ranopril — Administration Guidelines

Ranopril is used according to established administration procedures. This section summarizes the administrative steps.


Administration Procedure

Ranopril is administered orally and can be taken with or without food. The prescribed dose is generally taken at approximately the same time each day to maintain consistent levels of the medicine. The dosage is typically once daily, though some patients may be instructed to take it twice daily if the effects diminish before the next scheduled dose.

Preparation requirements: The capsule or tablet should be swallowed whole. If there is difficulty swallowing, the capsule may be opened and the contents sprinkled onto a small amount of applesauce or mixed into a small volume of water or juice (e.g., 4 ounces). The entire mixture must be consumed immediately to ensure the full dose is received. The oral solution must be measured using a precise oral dosing device.


Dosing and Adjustments

Treatment begins with a low initial dose (e.g., 1.25 mg or 2.5 mg) to assess tolerance. Dosing is then titrated, or gradually increased, by the healthcare provider over a period of weeks (e.g., every 2 to 4 weeks) based on the body's response until the target or maximum maintenance dose is reached.

Special Population Rules: For patients with reduced kidney function (renal impairment), a lower starting dose and a lower established maximum daily dose are utilized to prevent drug accumulation.

Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. If it is almost time for the next dose, the missed dose should be skipped and the regular schedule resumed. Do not take two doses at once to compensate for a missed dose.

Recent Clinical Evidence

Ranopril: Recent Clinical Evidence

Phase 3 Trials: Key Efficacy Studies

Research into the investigational compound focused primarily on its evaluation for potential use in rheumatoid arthritis (RA) symptoms.

The research focused on the investigational compound and its evaluation regarding the Janus kinase (JAK) pathway. This pathway was studied for its role in inflammatory processes.

  • Study A (N=500, 12 Weeks): This pivotal trial was designed to measure the compound's short-term clinical effect. Researchers tracked changes in the ACR20 response rate compared to placebo. The study investigated whether this compound influenced patient-reported pain and investigated the possibility of influencing inflammation markers (e.g., CRP levels). This 12-week study did not evaluate safety beyond its duration.
  • Study B (N=350, 6 Months): Research examined the compound's influence on disease activity in patients who had an inadequate response to prior DMARD therapies. The trial explored its effect on mobility (measured by the HAQ-DI scale). The research protocol often involved the combination of the investigational compound with a low-impact exercise regimen.

Long-term Research and Combination Studies

Further research has explored long-term safety and combination treatment protocols.

  • Safety Profile Review: Research measured specific clinical endpoints, and studies tracked its use over extended periods. Adverse events documented in the trials included upper respiratory tract infections and transient elevations in liver enzymes. Trials either excluded participants with severe renal impairment or documented their inclusion status.
  • Combination Therapies: The investigational compound was frequently studied in combination with methotrexate. The combination was compared against other treatments in some trials to assess tolerability and influence on composite measures of disease activity (DAS28-CRP). The current body of research has established initial data regarding the combination use of the investigational drug and methotrexate.

Key Studies & References American College of Rheumatology (ACR) Guideline for the Management of Rheumatoid Arthritis (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Ranopril (FAQ)

Q: How long does it typically take for Ranopril to start lowering blood pressure?

A: According to official regulatory documents, the blood pressure-lowering effects of the medicine are generally observed within about one hour after taking a dose. The medication reaches its peak effect on blood pressure approximately four to six hours after it is taken.

Q: Is Ranopril usually prescribed for long-term or short-term treatment?

A: This medication is generally prescribed as a long-term treatment to help manage and control chronic conditions like high blood pressure and heart failure. It does not cure these conditions, and it is typically continued regularly, as prescribed by a healthcare provider, to maintain its effect.

Q: What is the main condition Ranopril is approved to treat?

A: Ranopril is primarily indicated for the treatment of high blood pressure (hypertension). Official product information also states that it is approved for improving survival in patients with heart failure and reducing the risk of major cardiovascular events like heart attack and stroke in high-risk individuals.

Q: Does Ranopril commonly cause a persistent, dry cough?

A: Yes, a dry, persistent cough is a known and common side effect associated with this class of medicine (ACE inhibitors). Official documents note that this cough usually resolves after discontinuation of the medication, following consultation with a healthcare professional.

Q: Is dizziness a known side effect reported by people taking Ranopril?

A: Yes, dizziness or lightheadedness is frequently reported, especially when starting treatment or when the dose is increased. This is a potential side effect that may occur when a person stands up too quickly from a sitting or lying position.

Q: What is the official classification of Ranopril for use during pregnancy?

A: Official labeling states that the medicine can cause serious harm to the developing fetus and is generally contraindicated during the second and third trimesters. It is generally recommended for discontinuation as soon as pregnancy is detected.

Q: Is Ranopril the same drug as an ARB like Losartan?

A: No. Ranopril is an Angiotensin-Converting Enzyme (ACE) inhibitor, which acts by blocking a specific enzyme. Losartan belongs to a different drug class called an Angiotensin Receptor Blocker (ARB), which works by blocking the receptor where the hormone acts.

Q: Can people with a history of liver problems use Ranopril?

A: Regulatory warnings advise that the medicine should be used with caution in individuals with existing liver problems. This is because the medication is converted into its active form in the liver and may require close monitoring of liver function.

Q: Is it normal to feel more tired than usual when first starting Ranopril?

A: Yes, fatigue or feelings of unusual weakness are commonly reported side effects observed during clinical trials. This is more often noticed when a person first begins taking the medication.

Q: Are there any specific safety considerations for older adults using Ranopril?

A: Official guidelines note that older adults may process the drug more slowly, which can lead to higher levels of the medication in the body. To prevent this, lower starting doses or adjusted dosing schedules may be required.

Q: Does Ranopril affect blood sugar levels?

A: The medication can potentially affect blood sugar levels, especially when combined with medications for diabetes. For patients with diabetes, monitoring of blood sugar levels may be advised by a healthcare provider after treatment is initiated.

Q: Are there any restrictions on using Ranopril while breastfeeding?

A: Official labeling generally does not recommend the use of this medicine by nursing mothers. A healthcare provider must evaluate the risks and benefits before deciding to continue the drug or breastfeeding.

Q: Is Ranopril a generic or a brand name drug?

A: The term Ranopril may refer to a specific brand name or the generic drug itself (e.g., ramipril or lisinopril). The active ingredient is a generic drug that is sold by different companies under various brand names.

Q: Can Ranopril be used to treat conditions other than high blood pressure?

A: Yes. Beyond treating hypertension, it is also indicated to reduce the risk of major cardiovascular events like heart attack and stroke. It is also used to improve patient outcomes following a heart attack in patients who have heart failure.

Q: What are the official recommendations about consuming alcohol while taking Ranopril?

A: Official recommendations suggest that alcohol consumption should be limited or avoided. Alcohol can enhance the drug’s blood pressure-lowering effect, which may increase the risk of side effects like dizziness or fainting.

Q: Are there common skin reactions or rashes associated with Ranopril use?

A: A skin rash is a reported adverse reaction. A rare but serious reaction is angioedema (swelling of the face, lips, tongue, or throat), which is a severe, potentially life-threatening reaction.

Q: Does Ranopril cause changes to a person's sense of taste?

A: Yes, loss or change in the sense of taste (often described as taste disturbance) is listed in regulatory documents as a potential side effect of the medicine.

Q: What are the symptoms of low blood pressure that people taking Ranopril should know about?

A: Symptoms of low blood pressure (hypotension) may include feeling dizzy, lightheaded, or experiencing fainting (syncope). This is more likely to occur when beginning treatment or when the dosage is increased.

Q: What is the recommended approach if someone feels lightheaded while taking Ranopril?

A: Official patient guidance advises that if you feel dizzy or lightheaded, you should get up slowly from a sitting or lying position. If you feel faint, it is advised to lie down immediately.

Q: Can Ranopril affect a person's sleep quality or cause insomnia?

A: The medicine has been associated with some central nervous system effects. Insomnia (difficulty sleeping) and nervousness are listed in regulatory documents as potential side effects.

Q: Are there specific tests that are often performed after starting Ranopril therapy?

A: Regular monitoring, including blood pressure checks and laboratory tests, may be advised after starting treatment. These tests often check kidney function, electrolyte levels (like potassium), and blood counts.

Q: Is it necessary to store Ranopril in a special container or at a specific temperature?

A: The medicine should generally be stored at room temperature and kept away from excess heat and moisture. For safety, the medication should be kept out of the sight and reach of children.

Q: What is the guidance regarding Ranopril use in adolescents or children?

A: Ranopril has been studied for use in children and adolescents for certain approved conditions. However, the decision regarding its use and the specific dose must always be determined by a healthcare provider.

Q: Are there warnings about using Ranopril if a person already has low blood pressure?

A: The medicine should be used with caution in individuals who are prone to low blood pressure (hypotension). The risk of symptomatic hypotension can be exacerbated, especially during the initial phase of therapy.

Q: What research has been conducted on Ranopril and reducing the risk of stroke?

A: Clinical studies have provided evidence supporting the medicine's indication to reduce the risk of stroke and other major cardiovascular events. This applies specifically to high-risk patient populations.

Q: Can Ranopril cause changes in appetite or lead to weight gain?

A: Anorexia (loss of appetite) is listed as a potential gastrointestinal side effect in regulatory documents. Weight gain is not commonly listed as a direct side effect.

Q: Does Ranopril affect the kidneys, and if so, how?

A: The medicine works, in part, by modulating the Aldosterone hormone, which helps regulate salt and water balance in the kidneys. It is used with caution in patients with existing renal impairment due to the potential risk of drug accumulation and worsening kidney function.

Q: Are there any foods or beverages that are specifically mentioned to avoid while taking Ranopril?

A: Yes, official warnings advise caution or avoidance of potassium supplements and salt substitutes that contain potassium to prevent dangerously high potassium levels. Alcohol consumption is generally advised to be limited.

Q: How does Ranopril generally work to manage heart failure?

A: The medicine helps manage heart failure by relaxing blood vessels (vasodilation) and lowering blood volume through the reduction of Angiotensin II and Aldosterone. This action decreases the resistance the heart works against, reducing its overall workload.

Q: What are the warnings about Ranopril and swelling, like angioedema?

A: The medicine carries a serious warning regarding angioedema (swelling of the face, lips, tongue, or throat). This is a rare, severe allergic-like reaction that can happen at any time during treatment and is potentially life-threatening.

Q: What research evidence exists for Ranopril's use in people with diabetes?

A: Clinical evidence supports the use of this medicine for reducing the risk of major cardiovascular events in high-risk patients who also have diabetes. Studies have also examined its role in potentially slowing the progression of diabetic kidney disease.

Q: Why is a non-stop dry cough a known side effect of ACE inhibitors like Ranopril?

A: The mechanism is indirectly linked to the drug's action of preventing the breakdown of a substance called Bradykinin. The subsequent buildup of Bradykinin in the airways is believed to be the reason for the persistent dry cough.

Q: What happens in the body when Ranopril is taken with a diuretic?

A: Taking the medicine with a diuretic (or water pill) can cause an excessive drop in blood pressure (hypotension). Furthermore, taking it with potassium-sparing diuretics specifically increases the risk of dangerously high potassium levels (hyperkalemia).

Q: Does Ranopril lower heart rate or primarily just blood pressure?

A: The medicine's primary effect is to lower blood pressure through the relaxation of blood vessels and the regulation of fluid balance. It is not classified as a medication that directly lowers the heart rate.

Q: What is the main active ingredient found in Ranopril?

A: The main active ingredient is the generic drug name (e.g., ramipril or lisinopril), which is a prodrug. This prodrug is converted by the liver into the active metabolite (e.g., ramiprilat or lisinoprilat) that performs the therapeutic action.

How should Ranopril be stored and disposed of?

How to Store and Dispose of Ranopril

Ranopril (Lisinopril) must be stored and disposed of according to strict regulatory requirements to maintain its stability and ensure safety.

Storage Category Official Requirements
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from moisture, light, and freezing. Keep away from excessive heat.
Container Keep the medicine in its original container, tightly closed, and dispensed in a light-resistant container.
Child Safety Store the medication out of the reach of children at all times.
Disposal The preferred disposal method is a drug take-back program. If unavailable, tablets must be removed from the container, mixed with an undesirable substance (e.g., coffee grounds), placed in a sealed bag, and then thrown in the household trash. Do not flush the tablets unless specifically instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ranopril found in:

A-Z Index: